ep strong sale may
better posit weather
evolv rapidli ep beat sale in-lin pre-releas
manag suppli chain minim disrupt relat
stabil china sale expect region roughli neutral sale
estim sale tie elect surgeri adv surgeri
anesthesia pandem increas demand crrt pd home-bas renal
rais sale project left ep unchang line guidanc
given uncertainti face suggest investor test sensit sale ep
rang assumpt use interact impact model reiter
outperform rate reduc target primarili due lower
target multipl driven part lower overal group multipl
patienc disciplin leav well-posit deploy capit
asset valuat compress bil capit management appear readi consid
strateg invest said would expect mgmt criteria remain focus
primarili deal leverag channel strength core compet make
sens drive accret growth op margin favor year
management guid due uncertainti relat
although experienc signific financi impact given
uncertainti relat potenti impact management provid guidanc
back away preliminari guidanc provid jan guidanc org
growth rptd ep
chang model increas sale leav ep
estim unchang in-lin new guidanc
valuat previous target price base multipl
previous ebitda unchang new target multipl
roughli line stock current trade multipl ev/ebitda risk
greater expect impact product delay failur reach lt goal
litig regulatory/qu issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc global manufactur provid
diversifi healthcar suppli equip area renal
one-year valuat scenario base
ev/ebitda ebitda bil
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
 close
addit detail takeaway
perform quarter led pd therapi ww patient volum increas
y/i partial off-set lower sale select in-cent hd product includ bax
exit in-cent hd bloodlin busi neg impact sale
mil mil context renal bax largest busi china
sale acut therapi mil mil organ vs cse driven
continu roll-out prixmax platform
growth quarter led commerci execut infus system well iv
solut management note mil distributor purchas ahead influenza season
also first quarter sale hemodynam monitor system
acquir part cheetah medic acquisit contribut mil sale
growth driven demand hospit pharmaci compound servic gener
inject partial off-set lower sale inhaled-in anesthesia product cyclo sale
quarter mil
manag cite new product launch eu includ finomel ready-to-
use triple-chamb bag parenter nutrit olimel oliv oil-bas parenter
compani cite strong commerci execut well benefit competit
suppli disrupt perform quarter mil vs mil last quarter
compani expect anesthesia busi neg impact result lower
although experienc signific financi impact given
uncertainti relat potenti impact management provid guidanc
time updat april conf call recal provid preliminari
outlook januari sale growth adj op mgn management provid
guidanc org growth rptd ep
 op margin bp estim
sale net cog tax share off-set sg deliv
ep oper margin bp estim cse gross
margin bp estim bp y/i result top line
perform favor mix well posit manufactur variat
estimate bpop bpnon-op bpnet chg y/i charl martineau univers toronto march
salesy/i chg cc cg org cg salesy/i chg cc cg org cg renal therapi charl martineau univers toronto march
chang model
increas sale leav ep estim unchang in-lin new
guidanc made rel minor adjust top-lin project
beyond increas leav year ep estim unchang
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
